Welcome to LookChem.com Sign In|Join Free
  • or
Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-2-nitro- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

657427-16-2

Post Buying Request

657427-16-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

657427-16-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 657427-16-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,5,7,4,2 and 7 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 657427-16:
(8*6)+(7*5)+(6*7)+(5*4)+(4*2)+(3*7)+(2*1)+(1*6)=182
182 % 10 = 2
So 657427-16-2 is a valid CAS Registry Number.

657427-16-2Relevant academic research and scientific papers

Method for preparing 1,4,7,10-tetraaza-2,6-pyridinophane

-

Paragraph 0030; 0035, (2017/08/28)

The invention relates to a novel method for preparing 1,4,7,10-tetraaza-2,6-pyridinophane. 2,6-dimethylamino pyridine serving as a raw material is subjected to amino protection through o-/p-nitrobenzenesulfonyl and reacts with N,N-di(2-chloroethyl)-o-/p-n

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

-

Page/Page column 42, (2010/02/14)

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatme

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme

-

Page/Page column 29, (2008/06/13)

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

NEW COMPOUNDS

-

Page/Page column 43, (2010/11/30)

The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, R, R1, R2, R3, R4, R5, R6, R7, m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 657427-16-2